Source link : https://www.newshealth.biz/health-news/jak-inhibitor-comes-up-short-in-phase-iii-crohns-disease-trial/
An investigational oral Janus kinase (JAK) inhibitor failed to meet most primary endpoints in a phase III trial of patients with moderate to severe Crohn’s disease, but the failures might have been due to problems with study design, an expert suggested. Across two induction studies in the DIVERSITY trial, a 200-mg dose of filgotinib met […]
Author : News Health
Publish date : 2024-12-06 17:23:25
Copyright for syndicated content belongs to the linked Source.